Ceapro Inc. (TSX-V: CZO OTCQX: CRPOF) (‘Ceapro‘ or the ‘Company’), today delivered an update on its development throughout its present organization.
On December 14, 2023, the Corporation announced it entered into a definitive settlement to combine operations with Aeterna Zentaris Inc. (‘Aeterna Zentaris’), a TSX and Nasdaq mentioned specialty biopharmaceutical organization, in an all-inventory merger of equals transaction to be effected by way of a program of arrangement beneath the Canada Company Firms Act (the ‘Arrangement’). The Arrangement is subject to many problems, like the acceptance of the Firm’s shareholders and optionholders (collectively, the ‘Securityholders’) at the particular conference of Securityholders scheduled for March 12, 2024 (the ‘Meeting’). In addition to the proposed Arrangement, the Company proceeds to execute on development throughout its ongoing improvement initiatives, as in-depth beneath.
‘We carry on to make promising progress across all parts of our business enterprise. Supplied the latest developments, we foresee that all essential good results elements will align to broaden our company product. By means of the planned merger with Aeterna Zentaris, we aim to turn into a merged business with high possible for price creation in the biopharmaceutical market. We glance forward to an exciting potential forward for the Firm and producing worth in the shorter and long time period for all stakeholders,’ stated Gilles Gagnon, M.Sc., MBA, President and CEO.
Avenanthramides (Avs): Phase 1-2a clinical demo getting carried out at the Montreal Overall health Institute: Following the productive completion of bioassays for measurement of Avs in human tissues, the trial is protecting rapid development forward. Since December 9, 2023, a few cohorts of eight wholesome topics have already been concluded with ascending doses from 30mg to 60mg and 120mg. No significant adverse activities have transpired with the 1st two doses and associates of the Info Protection Checking Board will entire the total examination of final results from the 120mg cohort in the course of the first week of March, becoming equipped to declare no matter whether the trial may perhaps be pursued as prepared and to give a environmentally friendly mild for the next dosage of 240mg. These effects are incredibly promising supplied that the larger the dose with out safety considerations, the more substantial the potential for extending to a variety of irritation-primarily based diseases.
Oat beta glucan powder (OBG): Samples of powder formulation have been effectively prepared and shipped to Symrise AG, Ceapro’s long-phrase companion, for liquid reformulation and evaluation for the Chinese sector.
Yeast beta glucan (YBG): Requirements have been standardized and the product or service is all set to be made use of for the PGX scale up projects in Edmonton and Austria. Relying on the thriving scale up of PGX engineering and approval from wellness authorities, this merchandise could be provided as an immune booster ahead of year finish 2024.
Enriched Oat Flour with Superior Focus of Avenanthramides: The very first batch has been properly generated. Samples have been sent to one particular key purchaser.
The Enterprise is assessing the potential of this solution for preventive antimicrobial houses when utilized to generate oat centered nutritional items.
New Merchandise Growth
Chewable Oat Beta Glucan (OBG): Ceapro’s team has successfully formulated a unique, standardized formulation for a nutritious confection which involves a higher concentration of OBG with each day dosage according to approved statements in 10 formulated nations.
Wellness Canada has approved Ceapro’s Novel Nutraceutical Item (NPN 80127493). The substantive promises derived from this approval consist of reduction of LDL cholesterol, supporting cardiovascular overall health reduction of Style 2 diabetic issues dangers, resource of fiber for the maintenance of basic superior wellness and guidance of a nutritious digestive system.
Ceapro’s group anticipates the official commercial launch of its accredited natural wellbeing products in H2, 2024, marking an important chapter in the Company’s journey toward advertising and marketing wellness while increasing its business enterprise product. According to Future Market Insights, the oat beta-glucan market is predicted to get to US$ 846.1 Million in 2032.
Whey Proteins: Working with its PGX Technological know-how, Ceapro and University of Alberta researchers properly processed in just one affordable step a extremely advanced combination that contains animal-primarily based proteins, and in individual whey proteins that are ordinarily discovered in liquid that remains right after cheese generation. Although these proteins are greatly utilised in activity beverages, baked merchandise, meal replacements, protein health supplements and toddler formulas because of to their identified dietary and purposeful houses, present-day professional purification procedures require quite a few ways and sizeable quantities of drinking water. PGX Technological know-how can be a extremely successful and economical option for this solution providing.
Outcomes from this ground-breaking research were being posted in the Journal of Food items Engineering in an post titled ‘Single-stage focus of whey proteins employing the pressurized fuel eXpanded (PGX) liquid engineering: Impact on physicochemical attributes and scale-up,’. They have also been submitted for a presentation at the 20th European conference on supercritical fluids in Maribor, Slovenia, May perhaps 26-29, 2024.
Technology
Pressurized Gas eXpanded Know-how (‘PGX Technology’)
Edmonton Primary Facility PGX Scale Up 50 Liters Vessel: The challenge continues to be on agenda. The mechanical aspect of the challenge is 100% accomplished and handle devices are 80% done. Pending receipt of remaining automation components, commissioning expected to be concluded by close of Q1 2024.
Natex Facility, Austria PGX Scale Up 100 Liters Vessel: The job stays on timetable. PGX tension vessel style and design is 100% accomplished. Initial protection and regulatory risk assessment has also been done. Commissioning is anticipated to be finished by close of Q3 2024.
Cosmeceutical Base Enterprise
From a business enterprise point of view, when 2023 was a challenging calendar year owing to a reorganization from a person major consumer in United states of america, we are happy to announce that this buyer has resumed ordering from Ceapro throughout Q1, 2024 with a +20metric ton purchase of avenanthramides.
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology business involved in the enhancement of proprietary extraction technological know-how and the software of this technologies to the creation of extracts and ‘active ingredients’ from oats and other renewable plant resources. Ceapro provides further more price to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics solutions for people and animals. The Business has a broad array of experience in all-natural product chemistry, microbiology, biochemistry, immunology and approach engineering. These expertise merge in the fields of energetic elements, biopharmaceuticals and drug-supply solutions.
Ahead-searching details
The facts in this news release has been well prepared as at February 22, 2024. Particular statements manufactured herein, including statements relating to issues that are not historical info and statements of the Firm’s beliefs, intentions and expectations about developments, results and occasions which will or may manifest in the foreseeable future, constitute ‘forward-looking information’ in the this means of relevant Canadian securities laws. Forward-looking info relates to foreseeable future situations or long term functionality, mirror current anticipations or beliefs relating to foreseeable future situations and is commonly identified by words this kind of as ‘aim’, ‘anticipate’, ‘assume’, ‘believe’, ‘continue’, ‘could’, ‘expect’, ‘forecast’, ‘future’, ‘intend’, ‘maintain’, ‘may’, ‘outlook’, ‘plan’, ‘potential’, ‘project’, ‘synergies’, ‘will’, and very similar expressions suggesting potential outcomes or statements relating to an outlook. Ahead-seeking info consists of, but is not constrained to, statements with respect to the Arrangement, like the anticipated timing and outcome of the Conference, closing and various other techniques to be accomplished in link with the Arrangement, and other statements that are not historical facts, which includes the Firm’s ability to acquire regulatory approvals, including these from wellness authorities, and to create, introduce, and put into practice new merchandise as perfectly as enhancements for existing goods that meet client wants and products specifications in a timely fashion.
Ahead-seeking data is primarily based upon specified assumptions and other essential elements that, if untrue, could induce the actual outcomes, performance or achievements of the Company or the put together firm to be materially diverse from long run success, general performance or achievements expressed or implied by these kinds of details. There can be no assurance that these information and facts will show to be accurate. This kind of data is based mostly on several assumptions, together with assumptions with regards to the capability to entire the Arrangement on the contemplated conditions or at all that the conditions precedent to closing of the Arrangement can be pleased, together with the well timed receipt of all important courtroom, regulatory, 3rd-celebration and Securityholder approvals present and foreseeable future company methods functions general performance in anticipated ranges market and industry anticipations prosperous and well timed product or service launches and the means to guard the Company’s intellectual residence.
Viewers are cautioned not to place undue reliance on ahead-looking details, which speak only as of the date created. For a a lot more detailed dialogue of such pitfalls and other variables that may possibly affect Ceapro’s ability to reach the expectations set forth in the forward-looking information and facts contained in this information launch, see Ceapro’s administration facts circular dated February 9, 2024, MD&A filed under Ceapro’s profile on SEDAR+ at www.sedarplus.ca, as effectively as Ceapro’s other filings with the Canadian securities regulators. Other than as essential by legislation, the Corporation does not intend, and does not believe any obligation to, update the ahead-hunting details in this news launch.
Call:
Jenene Thomas
Tel: +1 (833) 475-8247
E mail: [email protected]
Gilles R. Gagnon, M.Sc., MBA
President & CEO
Tel: 780-421-4555
